Dec 24 (Reuters) - Shares of Agios Pharmaceuticals (AGIO) jumped 18% on Wednesday after the U.S. Food and Drug Administration approved the expanded use of its drug for the treatment of a type of blood disorder.
The drug mitapivat is now approved as a treatment for patients with anemia in both non-transfusion-dependent and transfusion-dependent alpha- or beta-thalassemia, the company said late on Tuesday.
Thalassemia is an inherited blood disorder affecting the body's ability to produce hemoglobin and healthy red blood cells.
The drug, under the brand name Aqvesme, is expected to be available in late January next year, following the implementation of the required safety program.
Mitapivat was already approved by the U.S. FDA in 2022 to treat low red blood cell counts in adults with pyruvate kinase deficiency, under the brand name of Pyrukynd.
"The approval unlocks an additional $320 million in peak revenue opportunity layered atop the existing mitapivat franchise," Truist analyst Gregory Renza said.
The latest approval is based on a late-stage study in which patients receiving mitapivat showed a statistically significant increase in hemoglobin response compared to those on placebo.
Aqvesme will carry a boxed warning for liver function tests every four weeks during the first 24 weeks of treatment and advises against use in patients with cirrhosis, Renza added.
(Reporting by Siddhi Mahatole in Bengaluru; Editing by Vijay Kishore)
LATEST POSTS
- 1
Find the Insider facts of Viable Advertising: Building a Positive Brand Picture - 2Merck urges science-led US vaccine schedule after CDC trims childhood vaccine list
- 3Blue Origin's next space tourism flight will break new ground for people with disabilities
- 4The most effective method to Pick the Best Material Organization: Insider Tips
- 5Investigating Free Cell Phones: What You Really want to Be aware
- Lockheed Martin opens new hypersonic weapons facility
- Overhaul Your Rest: Tips for a Serene Evening
- The Tradition of Stone: A Gander at Notable Structures Through the Ages
- Pleasant Cycle Courses All over the Planet
- Marvel's X-Men are joining the battle in 'Avengers: Doomsday': Watch the teaser
- Make your choice for the music application with the most amicable connection point!
- Study reveals how fast weight returns after ending GLP-1 drugs
- Science is best communicated through identity and culture – how researchers are ensuring STEM serves their communities
- Instructions to Comprehend and Use Open Record Extra Offers
